PMID- 25828389
OWN - NLM
STAT- MEDLINE
DCOM- 20151103
LR  - 20151119
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 39
IP  - 9
DP  - 2015 Sep
TI  - MYC cytogenetic status correlates with expression and has prognostic significance 
      in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
PG  - 1250-8
LID - 10.1097/PAS.0000000000000433 [doi]
AB  - MYC/BCL2 double-hit lymphoma (DHL), defined by conventional cytogenetic or 
      fluorescence in situ hybridization (FISH) analysis, and MYC/BCL2 double-positive 
      lymphoma (DPL), defined by immunohistochemistry, are associated with a poor 
      prognosis. However, DHL and DPL are not concordant, and it is unclear whether MYC 
      and BCL2 aberrations have prognostic impact in DPL patients. In a cohort of 135 
      patients diagnosed with large B-cell lymphoma between 2010 and 2014 in whom 
      MYC/8q24 and BCL2/t(14;18)(q32;q21) statuses were assessed by FISH at diagnosis, 
      we evaluated MYC and BCL2 expression by immunohistochemistry. A total of 54 (40%) 
      cases were positive for MYC and BCL2 supporting DPL. Among them, 19 (35%) had MYC 
      rearrangement including 11 DHLs, 12 (22%) had multiple copies of MYC, 19 had no 
      MYC abnormalities, and in 4 cases FISH analysis failed. BCL2 abnormalities were 
      present in 28/54 (52%) cases (20 rearranged and 8 multiple copies). MYC 
      rearrangement correlated with a significantly worse overall survival in DPL 
      (P<0.05), whereas BCL2 genetic status did not correlate with survival (P>0.05). 
      MYC and BCL2 expression by immunohistochemistry correlates with gene status by 
      FISH; however, immunohistochemistry is neither specific nor adequately sensitive 
      to be used as a surrogate for MYC and BCL2 gene status using any cutoff level. In 
      conclusion, MYC rearrangement identifies a subset of patients with DPL who have a 
      significantly worse prognosis. Although immunohistochemical assessment for MYC 
      and BCL2 may be a helpful initial screen to identify higher-risk patients, FISH 
      analysis for MYC remains important for further risk stratification in patients 
      with DPL.
FAU - Wang, Xuan Julia
AU  - Wang XJ
AD  - *Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      School of Medicine, Nashville, TN daggerDepartment of Hematopathology, The University 
      of Texas MD Anderson Cancer Center, Houston, TX.
FAU - Medeiros, L Jeffrey
AU  - Medeiros LJ
FAU - Lin, Pei
AU  - Lin P
FAU - Yin, C Cameron
AU  - Yin CC
FAU - Hu, Shimin
AU  - Hu S
FAU - Thompson, Mary Ann
AU  - Thompson MA
FAU - Li, Shaoying
AU  - Li S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (BCL2 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Gene Rearrangement
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lymphoma, Large B-Cell, Diffuse/chemistry/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/analysis/*genetics
MH  - Proto-Oncogene Proteins c-myc/analysis/*genetics
MH  - Reproducibility of Results
MH  - Time Factors
MH  - Young Adult
EDAT- 2015/04/02 06:00
MHDA- 2015/11/04 06:00
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2015/11/04 06:00 [medline]
AID - 10.1097/PAS.0000000000000433 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2015 Sep;39(9):1250-8. doi: 10.1097/PAS.0000000000000433.